Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics-Reference-Cited by-同舟云学术

Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics

Published:2024-02-29 Issue:1 Volume:18 Page:42-48
ISSN:1881-7815
Container-title:BioScience Trends
language:en
Short-container-title:BST

Author:

Wu Jiayi¹²,Wu Junyi¹²,Li Shuqun¹³,Luo Mengchao¹⁴,Zeng Zhenxin¹,Li Yinan¹,Fu Yangkai¹,Li Han¹,Liu Deyi¹,Ou Xiangye¹,Lin Zhongtai¹⁴,Wei Shaoming¹⁴,Yan Maolin¹²

Affiliation:

1. Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.

2. Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian, China.

3. Department of Hepatobiliary Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.

4. Department of General Surgery, Fujian Provincial Hospital, Fuzhou, Fujian, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Link

https://www.jstage.jst.go.jp/article/bst/18/1/18_2023.01326/_pdf

Reference57 articles.

1. 1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022; 76:681-693.

2. 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209- 249.

3. 3. Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022; 11:227-252.

4. 4. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018; 391:1163-1173.

5. 5. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382:1894-1905.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study;BMC Cancer;2024-06-11